Clinical Trial Update: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating prexasertib (LY2606368) in extensive-stage small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Prexasertib (prexasertib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-17